[The interferon inducer neovir (kamedon) in the combined treatment of chronic inflammatory diseases of the adnexa uteri of chlamydial etiology (a clinical electron-microscopic study)].
One of the major factors of nonspecific immunity i.e. the state of the host interferon system was studied with a purpose of its correction in the treatment of inflammatory diseases of the uterine appendages of the chlamydial etiology. In all the female patients with chronic inflammatory diseases of the uterine appendages of the chlamydial etiology there was observed a disorder in the function of the interferon system link: a decrease in the concentration of blood serum interferon and a lower capacity of the blood cells to produce alpha- and gamma-interferons. The findings were used as a theoretical ground for the inclusion of neovir, an inductor of alpha-interferon to the treatment of such patients. After the completion of the treatment course with the use of neovir the index of the serum interferon proved to be higher than the normal by 2.4 log2IU and the indices of alpha- and gamma-interferons were lower than the normal only by 0.1 and 1.3 log2IU respectively. Therefore, the mechanism of the neovir action included activation of the function of the interferon endogenic system. The morphometrical analysis of the number of the cytoplasmic granules of the polymorphonuclear leukocytes in the peripheral blood before, during and after the therapy with neovir and pefloxacin showed that neovir not only promoted restoration of the digestion function of the neutrophilic leukocytes but also markedly activated it which provided a success of the phagocytic attack.
V V
VV
Delektorskiĭ
V V
VV
Malinovskaia
A N
AN
Strizhakov
G N
GN
Iashkova
Zh A
ZhA
Kagramanova
D D
DD
Genkin
V V
VV
Parfenov
D Sh
DSh
Galiautdinov
A N
AN
Balandin
T V
TV
Lebedeva
D000166:Acridines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D002690:Chlamydia Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D003594:Cytoplasmic Granules / Q000187:drug effects / Q000648:ultrastructure; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000627:therapeutic use; D008854:Microscopy, Electron; D009504:Neutrophils / Q000187:drug effects / Q000648:ultrastructure; D015366:Pefloxacin / Q000627:therapeutic use; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors
D000166:Acridines; D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; D008070:Lipopolysaccharides; C009136:pyrogenal; C077681:Camedon; D015366:Pefloxacin
Induktor interferona--neovir (kamedon) v kompleksnom lechenii khronicheskikh vospalitel'nykh zabolevaniĭ pridatkov matki khlamidiĭnoĭ étiologii (kliniko-élektronnomikroskopicheskoe issledovanie).